Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Daré Bioscience announces funding award to further the development of Ovaprene™ from the National Institutes of Health Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
SAN DIEGO , April 30, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc.  (NASDAQ:DARE), a clinical-stage, women’s biopharmaceutical company, today announced that it received a Notice of Award for the first $224,665 of the anticipated $1.9 million in grant funding from the Eunice Kennedy Shriver
View HTML
Toggle Summary Daré Bioscience, Inc. Enters into Exclusive Worldwide License Agreement for Juniper Pharmaceuticals’ Intravaginal Ring (IVR) Technology Platform
The intravaginal ring technology platform is designed to deliver targeted and sustained pharmaceutical formulations addressing unmet needs in women’s health SAN DIEGO , April 25, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc.  (NASDAQ:DARE), a clinical-stage, women’s biopharmaceutical company
View HTML
Toggle Summary Jessica Grossman, M.D., Joins Daré Bioscience Board of Directors
SAN DIEGO , April 11, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc.  (NASDAQ:DARE), a clinical-stage, women’s biopharmaceutical company, today announced the appointment of Jessica Grossman , M.D., to its board of directors. Dr. Grossman is currently the CEO of Medicines360, a global nonprofit
View HTML
Toggle Summary Daré Bioscience, Inc. Reports 2017 Financial Results and Provides Business Update
-Conference Call and Webcast Today, April 2 nd , at 4:30 PM Eastern Time - SAN DIEGO , April 02, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc.  (NASDAQ:DARE), a clinical-stage, women’s biopharmaceutical company, today announced financial results for the full year ended December 31, 2017.
View HTML
Toggle Summary Daré Bioscience, Inc. to Announce Full Year 2017 Financial Results and Host a Live Conference Call and Webcast on Monday, April 2, 2018
SAN DIEGO , March 29, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc.  (NASDAQ:DARE), a clinical-stage, women’s biopharmaceutical company, announced that it has released financial results for the full year ended December 31, 2017 and will host a live conference call and webcast on Monday, April 2 nd
View HTML